Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.

Lee GC, Liou H, Yee R, Quan CF, Neldner K.

Clin Ther. 2012 Dec;34(12):2297-300. doi: 10.1016/j.clinthera.2012.11.005. Epub 2012 Nov 27.

PMID:
23195962
2.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group.

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
3.

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.

Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP Jr.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):236-40. doi: 10.1016/j.diagmicrobio.2009.03.002.

PMID:
19500529
4.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

PMID:
17205441
5.

Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

Winstead EM, Ratliff PD, Hickson RP, Mueller JE, Judd WR.

Int J Clin Pharm. 2016 Oct;38(5):1087-93. doi: 10.1007/s11096-016-0334-1. Epub 2016 Jun 22.

PMID:
27333796
6.

Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.

Arnold HM, Hollands JM, Skrupky LP, Smith JR, Juang PH, Hampton NB, McCormick S, Reichley RM, Hoban A, Hoffmann J, Micek ST, Kollef MH.

Ann Pharmacother. 2013 Feb;47(2):170-80. doi: 10.1345/aph.1R523. Epub 2013 Jan 22.

PMID:
23341160
7.

Rationale and evidence for extended infusion of piperacillin-tazobactam.

Kaufman SE, Donnell RW, Hickey WS.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1521-6. doi: 10.2146/ajhp100694. Review.

PMID:
21817083
8.

Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.

Brunetti L, Poustchi S, Cunningham D, Toscani M, Nguyen J, Lim J, Ding Y, Nahass RG.

Ann Pharmacother. 2015 Jul;49(7):754-60. doi: 10.1177/1060028015579427. Epub 2015 Apr 8.

PMID:
25855703
9.

Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.

Cutro SR, Holzman R, Dubrovskaya Y, Chen XJ, Ahuja T, Scipione MR, Chen D, Papadopoulos J, Phillips MS, Mehta SA.

Antimicrob Agents Chemother. 2014 Aug;58(8):4470-5. doi: 10.1128/AAC.02759-14. Epub 2014 May 27.

10.

Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.

D'Agostino C, Rhodes NJ, Skoglund E, Roberts JA, Scheetz MH.

J Infect Chemother. 2015 Oct;21(10):742-6. doi: 10.1016/j.jiac.2015.05.010. Epub 2015 Jun 9.

PMID:
26143049
11.

Development and implementation of a piperacillin-tazobactam extended infusion guideline.

Heinrich LS, Tokumaru S, Clark NM, Garofalo J, Paek JL, Grim SA.

J Pharm Pract. 2011 Dec;24(6):571-6. doi: 10.1177/0897190011406984.

PMID:
21676847
12.

Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.

Mah GT, Mabasa VH, Chow I, Ensom MH.

Ann Pharmacother. 2012 Feb;46(2):265-75. doi: 10.1345/aph.1Q378. Epub 2012 Jan 24. Review.

PMID:
22274145
13.

Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.

Bao H, Lv Y, Wang D, Xue J, Yan Z.

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):459-466. doi: 10.1007/s10096-016-2819-1. Epub 2016 Oct 28.

14.

Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.

Yusuf E, Spapen H, Piérard D.

J Crit Care. 2014 Dec;29(6):1089-95. doi: 10.1016/j.jcrc.2014.07.033. Epub 2014 Aug 7. Review.

PMID:
25179412
15.

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Dulhunty J, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Roberts JA; DALI Study Group.

J Antimicrob Chemother. 2016 Jan;71(1):196-207. doi: 10.1093/jac/dkv288. Epub 2015 Oct 3.

PMID:
26433783
16.

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Kim A, Sutherland CA, Kuti JL, Nicolau DP.

Pharmacotherapy. 2007 Nov;27(11):1490-7.

PMID:
17963458
17.

Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.

Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR.

Int J Antimicrob Agents. 2006 Aug;28(2):122-7. Epub 2006 Jul 3.

PMID:
16815689
18.

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.

Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.

Int J Antimicrob Agents. 2005 Jan;25(1):62-7.

PMID:
15620828
19.

Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.

Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.

Int J Antimicrob Agents. 2009 Nov;34(5):429-33. doi: 10.1016/j.ijantimicag.2009.07.004. Epub 2009 Sep 1.

PMID:
19726163
20.

Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.

Gonçalves-Pereira J, Oliveira BS, Janeiro S, Estilita J, Monteiro C, Salgueiro A, Vieira A, Gouveia J, Paulino C, Bento L, Póvoa P.

PLoS One. 2012;7(11):e49845. doi: 10.1371/journal.pone.0049845. Epub 2012 Nov 21.

Supplemental Content

Support Center